Global crises and a tough funding environment mean biopharma leadership teams need to work hard to survive, let alone thrive. Industry executives shared their predictions and advice on strategy for 2024.

Turnstone’s initial public offering comes just one week after Apogee and Sagimet launched US IPOs. Also, Westlake Village BioPartners raised $450m for its third venture capital fund and argenx grossed $1.27bn in a post-Phase III follow-on offering.

Improving human health is the raison d’etre of the biopharma sector. But what can the industry do to safeguard and improve the health of Planet Earth? Executives shared their thoughts with Scrip.

Private Company Edition: The amount of venture capital raised by biopharma firms fell but individual companies grabbed a lot of cash, making for a remarkable Q2 relative to pre-pandemic times. Recent Q3 rounds includes Frontera’s $160m series B. Also, Oxford Science Enterprises added €250m to its fund.